A Randomized Placebo-Controlled Trial of Leronlima
Post# of 148101
(Total Views: 466)
Posted On: 11/13/2024 9:59:18 AM
A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19
Findings
Overall, 84 participants were randomized and treated with leronlimab (n = 56) or placebo (n = 28). No difference was observed in change in total symptom score (P = 0.8184) or other pre-specified secondary endpoints between treatments. However, in a post hoc analysis, 50.0% of participants treated with leronlimab demonstrated improvements from baseline in National Early Warning Score 2 (NEWS2) at day 14, compared with 20·8% of participants in the placebo group (post hoc; p = 0.0223). Among participants in this trial with mild-to-moderate COVID-19 adverse events rates were numerically but not statistically significantly lower in leronlimab participants (33.9%) compared with placebo participants (50.0%).
https://www.sciencedirect.com/science/article...1824002601
Credit bluemoon in IV
Findings
Overall, 84 participants were randomized and treated with leronlimab (n = 56) or placebo (n = 28). No difference was observed in change in total symptom score (P = 0.8184) or other pre-specified secondary endpoints between treatments. However, in a post hoc analysis, 50.0% of participants treated with leronlimab demonstrated improvements from baseline in National Early Warning Score 2 (NEWS2) at day 14, compared with 20·8% of participants in the placebo group (post hoc; p = 0.0223). Among participants in this trial with mild-to-moderate COVID-19 adverse events rates were numerically but not statistically significantly lower in leronlimab participants (33.9%) compared with placebo participants (50.0%).
https://www.sciencedirect.com/science/article...1824002601
Credit bluemoon in IV
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼